INTRODUCTION
Hematopoietic growth factors, like granulocyte colony stimulating factor (G-CSF), have clinical indications for the treatment of cytopenias due to chemotherapy or radiotherapy. To accelerate hematopoietic regeneration, G-CSF has resulted in shortened duration of neutropenia [1] [2] [3] by signaling through its receptor, G-CSFR, which is expressed on non-hematopoietic and hematopoietic cells, including hematopoietic stem cells (HSCs) [4] .
HSCs reside adjacent to bone marrow (BM) endothelial cells (ECs) [5] . These ECs provide instruction to HSCs in both homeostasis and following myelosuppressive stress [6] [7] [8] [9] [10] . Transplantation of ECs can restore hematopoiesis, even following lethal-dose total body a Division of Hematologic Malignancies and Cellular Therapy, irradiation [11] [12] [13] . Even without transplantation of ECs, ECderived soluble factors are sufficient to expand hematopoietic cells [14] [15] [16] [17] . Recently, we described that pharmacologic administration of epidermal growth factor (EGF) resulted in both a 10-fold expansion of HSC-repopulating capacity and survival advantage compared with controls following radiation injury [18] . While EGF may be a radiation mitigator, its role in HSC regeneration following chemotherapy and how EGF compares with G-CSF for treatment of chemo-induced myelosuppression are yet to be determined. These questions are translationally relevant since the mechanisms for hematopoietic injury following radiation can differ from those following chemotherapy injury. For example, differences in patterns of damage to hematopoietic cells exist following 5-fluorouracil (5-FU) compared with radiation [19] . Moreover, the morphology of damaged sinusoidal ECs may be discontinuous and hemorrhagic following ionizing radiation, which differs from ECs observed following 5-FU, where ECs were nondiscontinuous and non-hemorrhagic [20] . These differences in the response of both HSCs and ECs to chemotherapy or radiation suggest that there could be differences in the marrow's response to growth factors as well.
The goal of this study is to characterize the hematopoietic response to both myelosuppressive and lethal-dose chemotherapy following EGF. Here, we demonstrate that EGF expanded HSCs and prolonged survival following 5-FU compared with saline-treated mice. Using mice with deletion of Bax in VEcadherin-expressing cells, we confirmed the fundamental role of ECs in facilitating hematopoietic regeneration. EGF increased G-CSFR expression, and mutually, G-CSF increased both EGF receptor (EGFR) and phosphorylation of EGFR. Translationally, in humans, 5-FU increases EGFR expression, and G-CSF in healthy human donors increases both EGFR and phosphorylation of EGFR. Taken together, these data demonstrate that EGF and G-CSF are synergistic to promote hematopoietic regeneration and could be given as dual therapy to patients with EGFR-negative malignancies undergoing chemotherapy treatment.
MATERIALS AND METHODS

Animals and Chemical/Biologic Reagents
Eight to 12-week old C57Bl6 (CD 45. 2 1 ) and B6.SJL (CD 45.1 1 ) mice were purchased from Jackson Laboratory (Bar Harbor, ME). Biologic variables such as age, sex, and weight were matched. By breeding VECadherinCre;Bax FL/1 mice with Bax FL/FL mice, we generated both VECadherinCre;Bax FL/FL mice and VECadherinCre;Bax FL/1 . Duke University Animal Care and Use Committee has approved all animal studies.
5-Fluorouracil (Fresenius Kabi, Lake Zurich, IL) and 5-fluoro-2 0 -deoxyuridine 5 0 -monophosphate (FdUMP), an active metabolite of 5-FU (Sigma-Alrich, St. Louis, MO), were diluted with 1X PBS (Sigma-Alrich) to the specified concentrations.
Peripheral blood (PB) samples from both healthy donors and patients with colorectal cancer (CRC) were obtained using protocols approved by the Institutional Review Board at Duke University. Written and informed consents were obtained from all subjects. PB from healthy donors, donors mobilized with G-CSF, and patients with CRC was collected in heparinized tubes. For mobilization, donors were treated with daily injections of 10 lg/kg G-CSF per day for 5 days. Samples were collected and processed 2 hours after the last dose.
Early passage patient-derived cancer cell lines were cultured and developed as described previously [21] . CRC patients' specimens used to generate the cell lines were collected under a Duke IRB approved protocol (Pro00002435). These cell lines were then authenticated using the Duke University DNA Analysis Facility Human cell line authentication (CLA) service. Specifically, genomic DNA isolated from the cancer cell lines were analyzed for polymorphic short tandem repeat markers using the GenePrint 10 kit from Promega (Madison, WI) to ensure purity. HT-29, HCT-116, and NCI-H460 were obtained from American Type Culture Collection (Manassas, VA). Cultures of primary BM ECs were generated using methods described previously [18] .
Analysis for EGF, EGFR, and G-CSFR Expression
For mRNA expression of EGFR, cell subsets from C57Bl6 mice were collected at 24 hours following 150 mg/kg 5-FU, 0.5 mg/kg IV EGF (R&D Systems, Minneapolis, MN), or 0.5 mg/kg subcutaneously G-CSF. mRNA EGFR expression analyses and analysis for other targets (CDK1, CDK2, CDK4, CDK6, p21, PUMA, and BCl-2) were performed according to manufacturer's specifications (ThermoFisher Scientific, Waltham, MA). Relative expression of genes was calculated using deltadelta C T analysis with normalization to GAPDH.
For protein expression of EGFR, cell subsets were isolated according to manufacturer's specifications (Miltenyi Biotec, Auburn, CA). BM lineage-negative (lin -) cells were stained with CD34 APC (BD), anti-EGFR FITC (Abcam, Cambridge, MA), 7-AAD (BD), and anti-lineage antibody APC, anti-cKit PE, and anti-Sca-1 APC-Cy7 (BD, San Jose, CA). Phosphorylation of EGFR was performed using published methods [18] .
G-CSFR expression was determined using ckit 1 Sca 1 Lin-(KSL) antibodies (BD) and anti-G-CSFR antibody Alexafluor 488 (R&D Systems).
For phospho-EGFR of human cells, cells were labeled with CD341, and then cells were fixed and permeabilized as described [18] . Cells were labeled with anti-phospho-EGFR (Y1078) antibody (Cell Signaling, Danvers, MA). Isotype controls were included for all analyses.
Hematopoietic Progenitor Cell Assays and Survival Study
BM collection, mouse EC antigen-32 (MECA) staining, and colony forming cell (CFCs) methylcellulose assays were performed using published methods [18] . H&E staining were performed by the Duke Research Immunohistology Laboratory. For colony-forming unit-spleen 12 (CFU-S12) analysis, 2 3 10 5 whole BM (WBM) cells were injected into 900-cGy irradiated C57Bl6 mice. At day 12 post-injection, colonies were counted by two independent investigators. Complete blood counts were quantified on a HemaVet 950 (Drew Scientific, Dallas, TX). Long-term culture initiating cell (LTC-IC) assays were performed using published methods [22] .
Competitive transplantation assays were performed with 2 3 10 5 donor cells from B6.SJL mice at day 7 after 5-FU and days 1-4 of 0.5 mg/kg EGF or saline and injected into 900-cGy irradiated C57Bl6 mice with 2 3 10 5 host WBM cells. Secondary competitive transplantation assays were performed using 40% of BM cells from primary-transplanted mice and 2 3 10 5 host WBM cells. Each donor was transplanted into two recipient mice. Measurement of donor chimerism within the BM KSL population was performed at 16-weeks posttransplantation as described previously [18] . For the survival study, C57Bl6 mice were treated with 600 mg/kg IV 5-FU and then given 0.5 mg/kg EGF or saline beginning at 24 hours later and then daily through day 4. Mice were sacrificed when endpoints were met according to approved protocols from IACUC at Duke University.
HSC Cycling and Cell Death Assays
For cell cycle analysis, KSL-labeled cells were treated with Fix Buffer I, Perm Buffer III, Ki67-FITC, and 7-AAD according to manufacturer specifications (BD). For cell death analysis, KSL cells were sorted and cultured for 24 hours in 0.5 lM FdUMP with and without 20 ng/ml EGF in 20 ng/ml thrombopoietin, 125 ng/ml stem cell factor, and 50 ng/ml Flt-3 ligand (TSF) [18] compared with TSF alone. KSL cells and progeny were stained with annexin V FITC and 7-AAD according to manufacturer's specifications (BD).
Viability of cells were determined by tetrazolium blue (MTT, Sigma-Alrich) assay according to manufacturer's specifications.
Statistical Analyses and Image Capture
Data are shown as means 6 SEM. Student's t test (two-tailed with unequal variance) or Mann-Whitney analysis were used as specified in the figure legends. Survival analysis was performed using a Log-rank test. Analyses were performed using GraphPad Prism (v7.0, La Jolla, CA).
Images for immunohistochemistical analysis were obtained with Zeiss AxioImager Z2 and Axiocam 506. Immunofluorescent images were obtained with an Olympus BX61WI two photon system (Center Valley, PA). Adobe Photoshop software (20142.2, Adobe Systems, San Jose, CA) was used to quantify positive signals using methods previously described [23] . 
RESULTS
EGFR Expression Is Induced Following 5-FU
Following radiation, EGFR expression is enriched in KSL cells compared with more differentiated progenitor cells [18] . Untreated animals displayed increased EGFR expression in KSL cells compared with lin -cells (Supporting Information Fig.  S1A ). At 24 hours following 5-FU, KSL cells have a 10.5-fold increase in EGFR mRNA expression compared with untreated animals (Fig. 1A) (Fig. 1B) . Flow cytometric analysis for EGFR in both the WBM and lin -cell populations displayed less than 2% of EGFR1 cells in either untreated or 5-FU-treated animals. The percentage of EGFR1 cells within the KSL subset was increased 24.4-fold compared with WBM from untreated mice (Fig. 1C) . Comparison of the total KSL cells that are EGFR1 in untreated and 5-FU-treated mice show a modest increase in EGFR expression (Supporting Information Fig. S1B ). Taken together, following 5-FU, both mRNA and protein expression of EGFR is increased in hematopoietic cells, and particularly in KSL cells.
EGF Promotes HSC Reconstitution Following 5-FU
To determine whether EGF accelerates HSC reconstitution after 5-FU, C57Bl6 mice were treated with 5-FU and then EGF or saline starting 24 hours later, since growth factors like G-CSF are administered at 24 hours following chemotherapy ( Fig. 2A) . BM was analyzed on both day 4 and day 7, since with 5-FU, day 4 represents the hematopoietic nadir and regeneration has commenced by day 7 [19] . At these time points, EGF-treated mice displayed preserved BM cellularity with a 2.3-fold increase in total cells at day 7 in EGF-treated animals compared with saline-treated mice (Fig. 2B) . The marrow vasculature also demonstrated increased staining for ECs by MECA (Fig. 2C ). EGF-treated mice increased CFCs and CFU-S12 compared with saline-treated mice ( Fig. 2B-2D ). LTC-IC assays, which are in vitro assays that linearly correlate with HSC function in vivo [24, 25] , demonstrated a 7-fold increase in long-term HSCs in EGF-treated mice compared with salinetreated mice (Fig. 2E) .
Complementary to LTC-IC assays, we performed competitive transplantation assays. Primary donor engraftment in both the PB and marrow of recipients of WBM from EGF-treated animals had increased multi-lineage donor engraftment compared with recipients of saline-treated animals (Fig. 2F ). Secondary competitive transplants were performed in which BM from primary recipient mice was transplanted into lethally irradiated recipients with competing host WBM. As early as 4 weeks and throughout the period of monitoring until 16 weeks, recipients of EGF-treated donor cell had increased PB engraftment compared with recipients of saline-treated donor cells (Fig. 2G, 2H ). Moreover, recipients of EGF-treated donors had both increased CD 45.1 chimerism and total KSL cells ( Fig. 2I, 2J ). These results indicate that pharmacologic treatment of EGF accelerated hematopoietic regeneration following myelosuppressive-dose 5-FU, particularly within the stem cell pool.
EGF Prolongs Survival Following Lethal-Dose 5-FU
To determine whether EGF prolongs survival following lethaldose 5-FU injury, C57Bl6 mice were treated with 600 mg/kg 5-FU and then EGF or saline from days 1 to 4 ( Fig. 2K ). Seventy percent of EGF-treated animals (7 of 10) survived through day 30. In contrast, only 20% of saline-treated animals (3 of 15) survived until day 30. These results demonstrate that EGF provides a survival advantage following lethaldose chemotherapy.
Deletion of Bax in VEcadherin1 ECs Is Chemoprotective of HSPCs
At 24 hours following 5-FU, the expression of Bax, a proapoptotic gene, is increased 2.8-fold in BM lin -cells from mice treated with 5-FU compared with untreated mice (Fig.  3A) . To abrogate apoptotic cell death in ECs, we used CreLoxP Fig. S2A ). Without injury to these mice, we detected no differences in complete blood counts, BM cellularity, BM EC structure or density, SLAM 1 KSL cells, or CFCs (Supporting Information Fig. S2B-S2F ).
We sought to determine whether prevention of chemotherapy-induced apoptotic cell death within VEcadherin 1 ECs would result in accelerated HSPC reconstitution. Following 24-hour cultures of BM lin -cells from each genotype with TSF 1 FdUMP or TSF alone, no differences were noted in total cell expansion, %KSL, and CFCs, suggesting that the hematopoietic phenotypes are equal (Supporting Information Fig. S2G ). The (Fig. 3E, 3F ). More specifically, Bax FL/FL mice had a 3.1-fold increase in MECA1 cells in their marrow compared with Bax FL/1 mice (Fig. 3E) . Similarly, total HSC content of Bax FL/FL mice was threefold greater compared with Bax FL/1 mice as estimated by LTC-IC assays (Fig. 3G ). These data demonstrate that Bax deficiency in VEcadherin-expressing cells could abrogate the myelosuppressive impact of 5-FU on HSCs in vivo. These data demonstrate that increased levels of EGF in vivo results in accelerated HSC regeneration following 5-FU myelosuppression.
Mechanisms of EGF Activity in HSPCs
We sought to determine whether EGF signaling could promote hematopoietic cell proliferation following chemotherapy. On day 4 following 5-FU, EGF-treated mice displayed increased Ki671 cells compared with saline-treated mice (Fig.  4A ). This increased level of Ki67 cells corresponded to increased KSL cells that were cycling in interphase (Fig. 4B) . Since cyclin-dependent kinases (CDKs) tightly regulate cell cycle [27] , we showed that EGF could upregulate CDK expression (CDK1, CDK2, and CDK6) and downregulate the CDK inhibitor p21 following chemotherapy (Fig. 4C) .
Since EGF mediated cell proliferation, we sought to determine whether EGF signaling could also mitigate chemoinduced cellular apoptosis. With the addition of EGF to KSL cell cultures treated with FdUMP, annexin1 cells were diminished compared with cultures with TSF alone (Fig. 4D) . In vivo, C57Bl6 mice treated with 5-FU and EGF displayed a 54% decrease in annexin1 cells compared with saline-treated control mice (Fig. 4E) .
Since 5-FU exerts its cytotoxic effects in part by generating lethal double-strand DNA (dsDNA) breaks [28] , we hypothesized that the decrease in annexin1 cells following EGF was by enhanced DNA repair [29] . Following 24 hours culture with FdUMP, EGF-treated KSL cells and progeny displayed a 40% reduction in percentage g-H2ax, a marker for DNA breakage, compared with cultures with TSF alone (Fig. 4F) . EGF may also facilitate dsDNA break repair through non-homologous end joining recombination via phosphorylation of DNA-protein kinase catalytic subunit (DNA-PKcs) [30] . Following 24 hours treatment with FdUMP and a 15-minute stimulation with EGF, C57Bl6 KSL cells display a 4.8-fold increase in phosphorylation of DNA-PKcs (T2637) compared with FdUMP treated cultures only (Fig. 4G, 4H ). The increase in phosphorylation of DNAPKcs corresponded to both a repression of PUMA and an increase in BCL-2 with EGF treatment (Fig. 4I ). These data demonstrate that EGF could mediate both cell proliferation and survival by increasing phospho-DNA-PKcs and via partial inhibition of PUMA signaling.
EGF Induces G-CSF Receptor Expression Following 5-FU
G-CSF is the clinical standard for treatment of myelosuppression following chemotherapy [1, 3] . We sought to determine whether dual therapy of G-CSF and EGF would be synergistic for hematopoietic regeneration compared with monotherapy with either EGF or G-CSF alone. On day 4 following 5-FU and G-CSF 1 EGF, C57Bl6 mice display increased marrow cellularity compared with G-CSF-treated mice (Fig. 5A) . Dual therapy resulted in both increased percentage and total SLAM 1 KSL compared with either G-CSF or EGF monotherapy (Fig. 5B) . The levels of SLAM 1 KSL cells in mice treated with G-CSF 1 EGF were 4.2-fold greater than in mice treated with either G-CSF or EGF monotherapy. This increase in SLAM 1 KSL corresponded to an increase in CFC content in mice treated with dual G-CSF 1 EGF compared with mice treated with monotherapy (Fig. 5C ). Based on LTC-IC analysis, G-CSF 1 EGF increased HSC content by 3.3-fold compared with either G-CSF or EGF alone (Fig. 5D ). These data suggest that dual therapy with G-CSF 1 EGF is synergistic to accelerate HSC regeneration. With either G-CSF or EGF, comparable levels of hematopoietic content were measured, which indicates that EGF could equally accelerate hematopoietic regeneration at the same levels as the current clinical standard G-CSF.
Since G-CSF and EGF can promote hematopoietic regeneration, we sought to determine whether G-CSF could modulate expression of EGFR, and conversely, whether EGF could modulate expression of G-CSF receptor (G-CSFR). This hypothesis is supported by reports that EGFR1 carcinomas could induce extreme leukocytosis, suggesting that EGF and hematopoietic growth factors other than exogenous G-CSF could promote leukocytosis via G-CSFR signaling [31, 32] . The gene that encodes G-CSFR Csf3r is increased 3.6-fold in KSL cells treated with chemotherapy and EGF compared with cultures with chemotherapy alone (Fig. 5E) . To model this study in vivo, we administered 5-FU to C57Bl6 mice and then administered EGF or saline and included an untreated control group (Fig. 5E ). Similar to EGFR, 24 hours following treatment with 5-FU induces Csf3r expression (Fig. 5E ). The addition of EGF administration further increases Csf3r expression by 3.6-fold compared with 5-FU treatment alone (Fig. 5E ). Corresponding to Csf3r mRNA expression, we measured the expression of G-CSFR protein and found that G-CSFR is increased 1.8-fold with 5-FU treatment compared with untreated controls (Fig. 5F) .
Similarly, treatment with 5-FU and EGF increased G-CSFR by 18 .5% compared with 5-FU alone (Fig. 5F ). These results indicate that EGF induces both mRNA and protein expression of G-CSFR following 5-FU.
Following chemotherapy and G-CSF, EGFR expression within KSL cells increased by 50% in vitro and by 45% in vivo compared with controls (Fig. 5G, 5H ). To determine whether this increased EGFR expression corresponded to increased Figure 5 .
Piryani, Kam, Kliassov et al. 9 www.StemCells.com V C AlphaMed Press 2017 EGFR signaling, the combination of 5-FU and G-CSF induced phosphorylation of EGFR (Y1173) compared with control mice (Fig.5I ). These data demonstrate that EGF upregulates G-CSFR at both the levels of mRNA and protein expression. Complementary to this finding, G-CSF upregulates EGFR expression following chemotherapy and promotes phosphorylation of the EGF receptor.
EGFR Expression in Humans Is Induced Following 5-FU and G-CSF In Vivo
To make these findings translationally relevant and validate the findings from our murine studies, we sought to determine whether EGF could promote cancer growth in cancer cell lines. We used two cancer lines that were generated from patients with colorectal liver metastasis (CRC119 and CRC240) [21] and three lines purchased from ATCC (HT-29, HCT-116, and NCI-H460). Following culture with 20 ng/ml EGF for 72 hours, HCT-116 displayed a modest increase in cell viability compared with control cultures in media alone (Supporting Information Fig. S3A ). All four other cell lines demonstrated no differences in cell expansion. Chemotherapy increased EGFR expression in CRC119 and in NCI-H460 and had no effect on other cell lines (Supporting Information Fig. S3B-S3D ). These data indicate that a subset of tumors does not respond to EGF treatment and that chemotherapy does not increase EGFR expression in all cancer cell lines at the time points and concentrations tested. Next, we examined whether 5-FU and G-CSF could modulate EGFR expression in vivo in humans. When patients with CRC were treated with 5-FU, the percentage of CD34 1 EGFR 1 cells was 4.4-fold greater compared with untreated cancer patients and was higher than in healthy human donors (Fig. 6A) . Following G-CSF injections, CD341 PB from healthy human donors displayed a 4.3-fold increase in EGFR compared with CD341 PB from untreated healthy human donors (Fig. 6B) . This corresponded to a modest increase in phosphorylation of EGFR (Y1078) in G-CSF-treated donors (Fig. 6C ). These data demonstrate that EGFR is both expressed and induced in vivo following treatment with either G-CSF or 5-FU.
DISCUSSION
We have previously demonstrated that EGF is a hematopoietic growth factor using a cytokine screen from murine marrow supernatants [33] . Next, we have shown previously that following ionizing radiation injury, EGF could promote HSC regeneration [18] . Although EGF regulates HSC regeneration following radiation, whether EGF also regulates HSC regeneration following chemotherapy was unknown. This distinction is clinically relevant since the mechanisms driving hematopoietic regeneration may not be directly transposable between radiation and chemotherapy. Since there are key differences in the response of both hematopoietic cells and sinusoidal ECs to myelosuppressive injury from radiation and chemotherapy, we sought to address these differences in these current studies.
We demonstrate that EGF accelerates HSC regeneration following 5-FU. While a single injection of 5-FU may not impair the repopulating capacity of HSCs [34] , 5-FU can both enrich the stem cell pool and induce functional changes on the enriched HSPC population [35] . 5-FU increased preferentially the expression of EGFR in HSPCs compared with more differentiated WBM cell populations. This expression of EGFR could prime both stem cells and stem/progenitor cells for EGF signaling to maximize the hematopoietic response when EGF is administered 24 hours later. Another mechanism by which EGF increased HSPCs is by increasing EC density in the marrow as measured by MECA1 vessels, thereby encouraging increased secretion of EGF. Using a pharmacologic approach by either supplementing EGF in cultures or EGF in vivo, we showed that increased levels of EGF resulted in increased HSC content after 5-FU. This increase in HSC content corresponded to an increase in myeloid progenitor engraftment, or a myeloid-bias following hematopoietic injury [18, 36] .
Complementary to these pharmacologic gain-of-function studies, we used a genetic approach using VECadherinCre;Bax FL/ FL (Bax FL/FL ) mice and littermate control mice. While baseline measurements of EGF were increased in Bax FL/FL ECs compared with Bax FL/1 ECs, treatment with FdUMP further increased levels of EGF in both genotypes. These increased levels of EGF resulted in increased HSC content and accelerated hematopoietic regeneration after 5-FU. These results demonstrate that EGF is a hematopoietic growth factor that accelerates regeneration after myelosuppressive chemotherapy.
The mechanism by which EGF promotes cellular proliferation following chemotherapy is by upregulation of cyclin dependent kinases, in particular CDK1, CDK2, and CDK6. Upregulation of these CDKs permits cell cycle progression. For cells to enter S-phase, levels of the CDK inhibitor p21 should be low [27, 37] . In our system, EGF represses p21 expression following chemotherapy. In a report from Sheng et al. [38] , EGF was shown to increase expression of p21 and promotes enterocyte proliferation. It is possible the effect of EGF on CDKs and CDK inhibitors is dose-dependent and could vary based on cell type (i.e., hematopoietic cells vs. enterocyte) and whether injury is present.
We demonstrate that dual therapy with G-CSF and EGF following 5-FU increased HSPC content within the marrow. When G-CSF and EGF are administered in combination following 5-FU, mice display increased HSPC compared with mice that received either agent alone, indicating the function of G-CSF has synergy with EGF. These findings are buffeted by a prior report that associated G-CSF and EGFR signaling [39] . Using a genetic approach, Ryan et al. localized the region that was responsible for G-CSF-mediated hematopoietic mobilization to a region within the EGFR locus [39] . Our data demonstrated increased hematopoietic stem/progenitor cell content in the marrow following 5-FU when G-CSF and EGF are coadministered. These data are consistent with published results showing that G-CSF and EGF treatment contributed to the retention of HSPCs in the marrow [39] . Without chemotherapy, EGF does not increase G-CSFR expression, and conversely, G-CSF does not alter EGFR expression. It is possible that this cross-induction of receptor expression requires an injured marrow, like that caused in the setting of chemotherapy. Finally, our results from murine models were validated in humans in which treatment with 5-FU increased levels of EGFR in CD341 hematopoietic cells in vivo. Moreover, treatment with G-CSF in healthy human donors showed a modest increase in phosphorylation of EGFR within the CD341 stem/ progenitor cell pool.
Although EGF is a known mitogen, culture of cancer cell lines with EGF increased cell viability in only one of five cell lines. This cell line HCT-116 displayed high levels of EGFR expression. EGFR expression or mutational status is not assessed in patients with CRC, since its status does not predict response to anti-EGFR therapies [40] . Additional screens of cell lines are required to predict whether EGF could be administered without encouraging cancer cell proliferation. The hematopoietic phenotype of mice with deficiency of EGFR or G-CSFR has been described previously [18, 41, 42] . Tissue-specific deletion of EGFR within cells of hematopoietic lineages resulted in no differences in complete blood counts nor ability to generate committed progenitors in methylcellulose assays in homeostasis [18] . Only following myelosuppressive radiation does the deficiency of EGFR delay hematopoietic stem/progenitor cell regeneration compared with animals with functional EGFR [18] . Mice that are deficient in G-CSFR have quantitatively decreased numbers of neutrophils, although these neutrophils have normal function and can emigrate appropriately to sites of inflammation [41] . Targeted deletion of the intracellular component of G-CSFR further impairs chemotaxis of neutrophils and neutrophil mobilization from the marrow following G-CSF administration [42] . These data demonstrate that G-CSFR is a major regulator of hematopoiesis in homeostasis, but whether EGFR and G-CSFR signaling are coordinated in response to myelosuppressive stressors are incompletely defined.
Clinical reports have suggested that EGF signaling might promote signal transduction through G-CSFR. Patient case studies suggest that a subset of lung carcinomas, of which about a 1/3 will bear EGFR-positive mutations [43] , could produce cytokines that cause extreme leukocytosis or a leukemoid reaction [32] , possibly by signal transduction through G-CSFR. For example, a patient with lung sarcomatoid carcinoma, that was highly positive for EGFR by immunohistochemistry, developed leukocytosis with 140 3 10 9 per liter WBC (normal range 3-10 3 10 9 per liter) in the absence of infectious symptoms and pharmacologic G-CSF treatment [32] . In a series of more than 550 patients with non-small cell lung cancers, 11% of patients presented with leukocytosis or thrombocytosis at the time of diagnosis [31] . This incidence of leukocytosis or thrombocytosis increases to 72% in patients with advanced-stage disease in non-small cell lung cancers and portends a poorer prognosis compared with patients without elevations in blood counts [31] . Other reports have suggested that EGFR-driven cancers could elaborate growth factors, including G-CSF and granulocyte-macrophage colony stimulating factor, to promote a cancer survival advantage [44] . Indeed, lung carcinoma in cultures supplemented with EGF had increased levels of G-CSF in the conditioned media compared with saline-treated cultures [45] . These data are suggestive that cancers with EGFR-positive mutations could promote leukocytosis. Whether leukocytosis was due to EGF and signal transduction through EGFR or G-CSFR remains to be defined. In addition, whether EGF preferentially binds to either EGFR or G-CSFR following 5-FU is still unknown.
CONCLUSION
EGF regulates HSC regeneration following myelosuppressive chemotherapy. When administered in combination with G-CSF, dual therapy results in synergistic activity. Translationally, EGF could be administered either as monotherapy or in combination with G-CSF to accelerate hematopoietic regeneration and improve the chances of cure for patients with EGFR-negative malignancies.
